Last Updated : April 30, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Edurant | Rilpivirine | HIV infection | List | Complete | ||
| Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
| Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | ||
| Byetta | Exenatide | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Trajenta | Linagliptin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Ozurdex | Dexamethasone intravitreal implant | Macular edema, central retinal vein occlusion | Do not list | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Benlysta | Belimumab | Systemic lupus erythematosus | Do not list | Complete | ||
| Lucentis | Ranibizumab | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete |
Last Updated : April 30, 2024